|
1
|
Gadakchi L, Hajialilo M, Nakhjavani MR, Abedi Azar S, Kolahi S, Gojazadeh M, Ebrahimi AA, Malek Mahdavi A, Noshad H and Khabbazi A: Efficacy and safety of mycophenolate mofetil versus intravenous pulse cyclophosphamide as induction therapy in proliferative lupus nephritis. Iran J Kidney Dis. 12:288–292. 2018.PubMed/NCBI
|
|
2
|
Jorge A, Wallace ZS, Zhang Y, Lu N, Costenbader KH and Choi HK: All-cause and cause-specific mortality trends of end-stage renal disease due to lupus nephritis from 1995 to 2014. Arthritis Rheumatol. 71:403–410. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Tedder TF and Engel P: CD20: A regulator of cell-cycle progression of B lymphocytes. Immunol Today. 15:450–454. 1994.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Ahuja A, Teichmann LL, Wang H, Dunn R, Kehry MR and Shlomchik MJ: An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus. J Immunol. 187:3888–3894. 2011.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Schioppo T and Ingegnoli F: Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther. 11:2891–2904. 2017.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Anderson DR, Grillo-Lo'pez A, Varns C, Chambers KS and Hanna N: Targeted anti cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C288)in the treatment of non-Hodgkin's B-cell lymphoma. Biochem Soc Trans. 25:705–708. 1997.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Haffner D and Fischer DC: Nephrotic syndrome and rituximab: Facts and perspectives. Pediatr Nephrol. 24:1433–1438. 2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Dent O: Methodological index for non-randomized studies. ANZ J Surg. 73:675–676. 2003.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Clark HD, Wells GA, Huët C, McAlister FA, Salmi LR, Fergusson D and Laupacis A: Assessing the quality of randomized trials: Reliability of the Jadad scale. Control Clin Trials. 20:448–452. 1999.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Boletis JN, Marinaki S, Skalioti C, Lionaki SS, Iniotaki A and Sfikakis PP: Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: A long-term prospective study. Nephrol Dial Transplant. 24:2157–2160. 2009.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Chavarot N, Verhelst D, Pardon A, Caudwell V, Mercadal L, Sacchi A, Leonardi C, Le Guern V, Karras A and Daugas E: Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study. Medicine (Baltimore). 96(e7429)2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Contis A, Vanquaethem H, Truchetet ME, Couzi L, Rigothier C, Richez C, Lazaro E and Duffau P: Analysis of the effectiveness and safety of rituximab in patients with refractory lupus nephritis: A chart review. Clin Rheumatol. 35:517–522. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Davies RJ, Sangle SR, Jordan NP, Aslam L, Lewis MJ, Wedgwood R and D'Cruz DP: Rituximab in the treatment of resistant lupus nephritis: Therapy failure in rapidly progressive crescentic lupus nephritis. Lupus. 22:574–582. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Gunnarsson I, Sundelin B, Jónsdóttir T, Jacobson SH, Henriksson EW and van Vollenhoven RF: Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum. 56:1263–1272. 2007.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hogan J, Godron A, Baudouin V, Kwon T, Harambat J, Deschênes G and Niel O: Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis. Pediatr Nephrol. 33:111–116. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Jónsdóttir T, Zickert A, Sundelin B, Henriksson EW, van Vollenhoven RF and Gunnarsson I: Long-term follow-up in lupus nephritis patients treated with rituximab-clinical and histopathological response. Rheumatology (Oxford). 52:847–855. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, Portales-Pérez D, Baranda L, Abud-Mendoza C and González-Amaro R: Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study. Arthritis Res Ther. 8(R83)2006.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Kotagiri P, Martin A, Hughes P, Becker G and Nicholls K: Single-dose rituximab in refractory lupus nephritis. Intern Med J. 46:899–901. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Melander C, Sallée M, Trolliet P, Candon S, Belenfant X, Daugas E, Rémy P, Zarrouk V, Pillebout E, Jacquot C, et al: Rituximab in severe lupus nephritis: Early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol. 4:579–587. 2009.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Pepper R, Griffith M, Kirwan C, Levy J, Taube D, Pusey C, Lightstone L and Cairns T: Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant. 24:3717–3723. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A and Moutsopoulos HM: Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: An open-label trial. Arthritis Rheum. 52:501–513. 2005.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Iaccarino L, Bartoloni E, Carli L, Ceccarelli F, Conti F, De Vita S, Ferraccioli G, Galeazzi M, Gatto M, Gerli R, et al: Efficacy and safety of off-label use of rituximab in refractory lupus: Data from the Italian Multicentre Registry. Clin Exp Rheumatol. 33:449–456. 2015.PubMed/NCBI
|
|
23
|
Iwata S, Saito K, Hirata S, Ohkubo N, Nakayamada S, Nakano K, Hanami K, Kubo S, Miyagawa I, Yoshikawa M, et al: Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus. Lupus. 27:802–811. 2018.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lateef A, Lahiri M, Teng GG and Vasoo S: Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience. Lupus. 19:765–770. 2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lindholm C, Börjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A and Bokarewa M: Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol. 35:826–833. 2008.PubMed/NCBI
|
|
26
|
Ramos-Casals M, García-Hernández FJ, de Ramón E, Callejas JL, Martínez-Berriotxoa A, Pallarés L, Caminal-Montero L, Selva-O'Callaghan A, Oristrell J, Hidalgo C, et al: Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 28:468–476. 2010.PubMed/NCBI
|
|
27
|
Arce-Salinas CA, Rodriguez-Garcia F and Gomez-Vargas JI: Long-term efficacy of anti-CD20 antibodies in refractory lupus nephritis. Rheumatol Int. 32:1245–1249. 2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Catapano F, Chaudhry AN, Jones RB, Smith KG and Jayne DW: Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus. Nephrol Dial Transplant. 25:3586–3592. 2010.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, Cairns TD and Lightstone L: Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis. 72:1280–1286. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, Soto-Vega E, Beltran-Castillo A, Jimenez-Hernandez M, Graillet D, Gonzalez L, Rojas-Rodriguez J, Pineda-Almazana A, et al: Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: A longitudinal analysis of 52 Hispanic patients. Lupus. 19:213–219. 2010.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Bang SY, Lee CK, Kang YM, Kim HA, Suh CH, Chung WT, Park YB, Choe JY, Kim TJ, Park YW, et al: Multicenter retrospective analysis of the effectiveness and safety of rituximab in korean patients with refractory systemic lupus erythematosus. Autoimmune Dis. 2012(565039)2012.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Tanaka Y, Takeuchi T, Miyasaka N, Sumida T, Mimori T, Koike T, Endo K, Mashino N and Yamamoto K: Efficacy and safety of rituximab in Japanese patients with systemic lupus erythematosus and lupus nephritis who are refractory to conventional therapy. Mod Rheumatol. 26:80–86. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Tsanyan ME, Soloviev SK, Radenska-Lopovok SG, Torgashina AV, Nikolaeva EV, Khrennikov YB and Nasonov EL: Clinical and morphological improvement of lupus nephritis treated with rituximab. Folia Med (Plovdiv). 56:245–252. 2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, et al: Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 62:2458–2466. 2010.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Chen J: Clinical efficacy and safety of low-dose rituximab combined with glucocorticoid in children with lupus nephritis. J Trauma Emergency. 6:2018.
|
|
36
|
Qiu ML, Jin O and Fang LK: Analysis of the Effect of small dose of rituximab in the treatment of systemic lupus erythematosus. China Foreign Medical Treatment. 32:2013.
|
|
37
|
Su GX, Wu FQ, Wang F, Zhou ZX, Huang XL and Lu J: Rituximab therapy for severe pediatric systemic lupus erythematosus. Zhonghua Er Ke Za Zhi. 50:697–704. 2012.PubMed/NCBI(In Chinese).
|
|
38
|
Fan ZY, Cai YB, Gu YY, Yang CD, Bao CD and Ye S: Efficacy of rituximab in patients with refractory severe systemic lupus erythematosus. Chin Remedies Clin. 9:2009.
|
|
39
|
Basu B, Roy B and Babu BG: Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis. Pediatr Nephrol. 32:1013–1021. 2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Goswami RP, Sircar G, Sit H, Ghosh A and Ghosh P: Cyclophosphamide versus mycophenolate versus rituximab in lupus nephritis remission induction: A historical Head-to-Head comparative study. J Clin Rheumatol. 25:28–35. 2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N, Meroni P, Messa P and Sinico AR: Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study. Rheumatology (Oxford). 53:1570–1577. 2014.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Li L, Luo FZ, Deng ZP and Wu BY: Application of rituximab in the treatment of severe and refractory lupus nephritis. J Nanjing Medical University (Natural Science edition). 34:2014.
|
|
43
|
Wu SH: Clinical efficacy of rituximab in the treatment of severe lupus nephritis. Road to Health. 9:2019.
|
|
44
|
Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, et al: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study. Arthritis Rheum. 64:1215–1226. 2012.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Zhang J, Zhao Z and Hu X: Effect of rituximab on serum levels of Anti-C1q and antineutrophil cytoplasmic autoantibodies in refractory severe lupus nephritis. Cell Biochem Biophys. 72:197–201. 2015.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, Cervera R, Doria A, Gordon C, Govoni M, et al: 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 78:736–745. 2019.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Tektonidou MG, Dasgupta A and Ward MM: Risk of End-Stage renal disease in patients with lupus nephritis, 1971-2015: A systematic review and Bayesian Meta-Analysis. Arthritis Rheumatol. 68:1432–1441. 2016.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Yap DYH and Chan TM: B Cell abnormalities in systemic lupus erythematosus and lupus nephritis-role in pathogenesis and effect of immunosuppressive treatments. Int J Mol Sci. 20(6231)2019.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Cassia M, Alberici F, Gallieni M and Jayne D: Lupus nephritis and B-cell targeting therapy. Expert Rev Clin Immunol. 13:951–962. 2017.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Sun CY, Shen Y, Chen XW, Yan YC and Yang CD: Distribution and significance of B-cell infiltrates in lupus nephritis. Chin J Rheumatol. 15:2011.
|
|
51
|
Jónsdóttir T, Gunnarsson I, Mourão AF, Lu TY, van Vollenhoven RF and Isenberg D: Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: Pooled data from two cohorts. Rheumatology (Oxford). 49:1502–1504. 2010.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J and Looney RJ: The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 48:455–459. 2003.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Alshaiki F, Obaid E, Almuallim A, Taha R, El-Haddad H and Almoallim H: Outcomes of rituximab therapy in refractory lupus: A meta-analysis. Eur J Rheumatol. 5:118–126. 2018.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Gladman DD, Ibañez D and Urowitz MB: Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 29:288–291. 2020.PubMed/NCBI
|
|
55
|
Zhong Z, Li H, Zhong H and Zhou T: Clinical efficacy and safety of rituximab in lupus nephritis. Drug Des Devel Ther. 13:845–856. 2019.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Stolyar L, Lahita RG and Panush RS: Rituximab use as induction therapy for lupus nephritis: A systematic review. Lupus. 29:892–912. 2020.PubMed/NCBI View Article : Google Scholar
|
